Register entry
- Registered sites
- 0
- Active NDC listings
- 3
- Labeller names
- 2
- Live patents
- 4
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
33 active NDC listings: 3 human prescription drug. By marketing category: NDA 2, ANDA 1.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 3 |
| Route | NDCs |
|---|---|
| oral | 3 |
| Labeller name on the listing | NDCs |
|---|---|
| travere therapeutics, inc. | 2 |
| travere therapeutics | 1 |
Exclusivity
Patents and exclusivities
4| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9662312 | FILSPARIsparsentan | use | Mar 2030 |
| 9993461 | FILSPARIsparsentan | use | Mar 2030 |
| Product | Exclusivity | Until |
|---|---|---|
| FILSPARISPARSENTAN | ODE-493 Orphan drug | Sept 2031 |
Catalogue
Marketed products
3| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Chenodal | Chenodiol | tablet, film coated, oral | 68974-876ANDA |
| FILSPARI | sparsentan | tablet, film coated, oral | 68974-200NDA |
| FILSPARI | sparsentan | tablet, film coated, oral | 68974-400NDA |
Enquiry
Common questions
- Is Travere Therapeutics, Inc. FDA approved?
- Travere Therapeutics, Inc. holds no registered establishment of its own; 3 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Travere Therapeutics, Inc. make?
- 3 products are listed under Travere Therapeutics, Inc. in the openFDA NDC Directory, most often as tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.